HENDERSON, NV / ACCESSWIRE / February 25, 2019 / The cost of healthcare has been outpacing inflation. According to Investor's Business Daily, the U.S. soon will ''spend nearly 20% of its gross domestic product on health care.'' Investors looking to cash in on this bullish signal could start by researching the following companies.
A company in the sector that has not had news recently but according to their website ''has an open IND (Investigational New Drug) and has agreed with the FDA on a Phase 2 trial protocol that is targeted to start at the end of Q2 of 2019'', BioRestorative Therapies, Inc. (BRTX), has grabbed our attention. The Company is developing therapies for the Global Chronic Low Back Pain Market (estimated of US$ 9.19 billion by 2025) and the Global Obesity Treatment Market ($15.6 billion by 2025.) *according to Grand View Research
Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), Achieve Life Sciences, Inc. (ACHV), Zosano Pharma Corporation (ZSAN), Pfizer Inc. (PFE).
BioRestorative Therapies, Inc. (BRTX) (Market Cap: $9.463M, Share Price: $0.7168), a life sciences company focused on stem cell-based therapies, is working on two major therapies. Their back-pain solution, BRTX-100, has shown positive results in both preclinical animal and human studies as a non-opioid chronic lower back pain treatment.
BRTX's obesity treatment ''ThermoStem'' uses brown adipose (fat) derived stem cells to generate brown adipose tissue (''BAT''). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.
BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span US, Australia and Japan. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels; this is a very promising sign for the company.
Achieve Life Sciences, Inc. (ACHV) (Market Cap: $22.18M, Share Price: $3.30), a clinical-stage biopharmaceutical company committed to the global development of cytisinicline for smoking cessation, announced final data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics (PK/PD) clinical study of cytisinicline in smokers. Per the details of the announcement, the study evaluated the repeat-dose PK and PD effects of 1.5 mg and 3.0 mg cytisinicline in 26 healthy volunteer smokers when administered over the standard 25-day course of treatment.
Zosano Pharma Corporation (ZSAN) (Market Cap: $54.357M, Share Price: $4.54) yesterday announced the completion of the second and final goal of the long-term safety study for Qtrypta, in which patients treated migraine attacks over a one-year period. The long-term data generated in this trial reinforced the well-tolerated safety profile and strong efficacy results previously reported in the six-month dosing portion of this safety study and in the randomized Phase 2/3 ZOTRIP pivotal study.
Pfizer Inc. (PFE) (Market Cap: $248.329B, Share Price: $42.96) announced the European Commission (EC) has approved ZIRABEV™ for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer and persistent, recurrent or metastatic carcinoma of the cervix.
This article was written by Regal Consulting, LLC (''Regal Consulting''). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. Regal Consulting has been compensated $50,000 cash for February services. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Full Legal Disclaimer Click Here.
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communication, LLC
View source version on accesswire.com: